Fresh Tracks Therapeutics (OTCPK:FRTX) - Cotización, noticias y análisis

Resumen de acción FRTX

Fresh Tracks Therapeutics, Inc. no tiene operaciones significativas.

FRTX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido un 5.8% al año en los últimos 5 años

No tiene una capitalización de mercado significativa ($5M)

Competidores de Fresh Tracks Therapeutics, Inc.

Aditxt

NasdaqCM:ADTX

US$4.0m

Ainos

NasdaqCM:AIMD

US$6.2m

AquaBounty Technologies

NasdaqCM:AQB

US$7.5m

Scorpius Holdings

NYSEAM:SCPX

US$6.1m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Fresh Tracks Therapeutics
Historical stock prices
Current Share Price	US$0.91
52 Week High	US$1.10
52 Week Low	US$0.45
Beta	0.49
1 Month Change	1.12%
3 Month Change	-7.13%
1 Year Change	78.45%
3 Year Change	-98.07%
5 Year Change	n/a
Change since IPO	-99.57%

Noticias y actualizaciones recientes

Recent updates

Brickell Biotech changes name to Fresh Tracks Therapeutics

Sep 07

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Aug 11

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

Apr 27

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

Jan 06

Brickell Biotech (BBI) Investor Presentation - Slideshow

Dec 02

Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26

Nov 18

Rentabilidad de los accionistas

	FRTX	US Biotechs	Mercado US
7D	1.1%	-0.2%	2.9%
1Y	78.5%	-1.0%	22.2%

Rentabilidad vs. Industria: FRTX superó al sector US Biotechs , que obtuvo un rendimiento del 0.7% el año pasado.

Rentabilidad vs. Mercado: FRTX superó al mercado US, que obtuvo un rendimiento del 24.9% el año pasado.

Volatilidad de los precios

Is FRTX's price volatile compared to industry and market?
FRTX volatility
FRTX Average Weekly Movement	4.3%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: FRTX no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de FRTX ha disminuido de 13% a 4% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2009	4	Bert Marchio	ir.frtx.com

Fresh Tracks Therapeutics, Inc. no tiene operaciones significativas. Anteriormente, la empresa se dedicaba al desarrollo de varias terapias de prescripción para el tratamiento de enfermedades autoinmunes, inflamatorias y otras enfermedades debilitantes en Estados Unidos. Fresh Tracks Therapeutics, Inc. se fundó en 2009 y tiene su sede en Boulder (Colorado).

Resumen de fundamentos de Fresh Tracks Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Fresh Tracks Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de FRTX
Capitalización bursátil	US$5.44m
Beneficios(TTM)	-US$5.69m
Ingresos (TTM)	US$8.01m

0.7x

Ratio precio-ventas (PS)

-1.0x

Ratio precio-beneficio (PE)

¿Está FRTX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de FRTX
Ingresos	US$8.01m
Coste de los ingresos	US$3.18m
Beneficio bruto	US$4.82m
Otros gastos	US$10.52m
Beneficios	-US$5.69m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.95
Margen bruto	60.25%
Margen de beneficio neto	-71.12%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado FRTX a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción FRTX

Recompensas

Análisis de riesgos

Competidores de Fresh Tracks Therapeutics, Inc.

NasdaqCM:ADTX

US$4.0m

NasdaqCM:AIMD

US$6.2m

NasdaqCM:AQB

US$7.5m

NYSEAM:SCPX

US$6.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Recent updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Price target increased to US$72.50

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus estimates of losses per share improve by 25%

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Brickell Biotech changes name to Fresh Tracks Therapeutics

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Consensus revenue estimates increase by 26%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Consensus revenue estimates increase by 159%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus revenue estimates fall by 47%

Price target decreased to US$2.67

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought US$134k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Brickell Biotech Advances To Phase III As It Eyes Commercialization

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

CEO & Director recently bought US$118k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Earnings beat expectations, revenue disappoints